Stomach Cancer Treatment Market Size & Share 2024-2032

Stomach Cancer Treatment Market Size

Stomach cancer treatment market size was valued at around USD 4.7 billion in 2023 and is estimated to grow at 13.5% CAGR from 2024 to 2032. Stomach cancer, also known as gastric cancer, is a type of cancer that begins in the stomach's lining. Treatment options include surgery (partial or total gastrectomy and lymphadenectomy), radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Palliative care is also essential for managing symptoms in advanced stages.

The rising incidence of stomach cancer is a significant driver for the market. For instance, according to World Cancer Research Fund International, the stomach cancer was the fifth most common cancer globally in 2022. It ranked as the fourth most common cancer in men and the seventh in women. Moreover, there were over 968,784 new cases of stomach cancer reported worldwide in 2022. Therefore, this underscores the critical need for advanced diagnostic and treatment solutions to address the growing prevalence of stomach cancer and improve patient outcomes.
 

Furthermore, advancements in diagnostic techniques, development of targeted therapies, rising awareness and screening programs, are the factors promoting the growth of the market.
 

Stomach Cancer Treatment Market Trends

Advancements in diagnostic techniques for stomach cancer have revolutionized the treatment landscape, offering profound benefits in early detection, personalized medicine, and treatment efficacy. These innovations are crucial as stomach cancer ranks among the most prevalent cancers globally, with significant implications for public health and patient outcomes.
 

• Improved diagnostic methods such as endoscopic ultrasound (EUS), computed tomography (CT) scans, and molecular diagnostics enable earlier detection of stomach cancer. Early detection often leads to more effective treatment options and better patient outcomes. Molecular diagnostics, in particular, play a crucial role in identifying specific genetic mutations and cancer biomarkers that can guide personalized treatment strategies and improve prognosis.
   
• Advanced diagnostic tools allow for personalized treatment plans tailored to individual patients based on their tumor characteristics. This approach can enhance treatment efficacy while minimizing unnecessary side effects.
   
• Additionally, novel imaging technologies and biomarker assays help oncologists monitor how tumors respond to treatment over time. This real-time feedback enables adjustments to therapy, optimizing the chances of successful outcomes. Thus, propelling the growth of the market.
   

Stomach Cancer Treatment Market Analysis

Based on type, the market is divided into chemotherapy, immunotherapy, and targeted therapy. The chemotherapy segment of the market is forecasted to reach USD 8.1 billion by 2032.
 

• Chemotherapy drugs, administered either orally or intravenously, are designed to kill rapidly dividing cancer cells. This property allows chemotherapy to shrink tumors in the stomach, can be particularly beneficial when the cancer is locally advanced or unresectable.
   
• For patients with advanced or metastatic stomach cancer where curative treatment is not possible, chemotherapy can help control the growth of cancer cells, alleviate symptoms such as pain and obstruction, and improve quality of life. Palliative chemotherapy aims to prolong survival and maintain or improve the patient's overall well-being.
   
• Further, chemotherapy is frequently used in combination with other treatment modalities such as radiation therapy or targeted therapies. Combining treatments can enhance their effectiveness through complementary mechanisms of action and may be tailored based on the specific characteristics of the cancer, thus driving the market growth.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on indication, the stomach cancer treatment market is segmented into gastric cancer /gastroesophageal junction cancer and gastrointestinal stromal tumors. The gastric cancer/ gastroesophageal junction cancer segment accounted for USD 3.3 billion in 2023.
 

• Advances in cancer diagnostic, such as endoscopic ultrasound (EUS) and computed tomography (CT) scans, along with improved biomarker testing, enable earlier detection of gastric cancer. Early diagnosis enhances treatment options and improves survival rates by catching the disease before it spreads.
   
• Surgical techniques for gastric cancer have evolved, offering more precise and less invasive procedures. Minimally invasive surgeries, such as laparoscopic and robotic-assisted surgeries, reduce recovery times, post-operative pain, and complications while improving outcomes.
   
• Additionally, molecular profiling and genetic testing allow for personalized treatment approaches. This means that treatments can be tailored to the specific genetic mutations and characteristics of the tumor, maximizing effectiveness and minimizing side effects. Thus, propelling the growth of the market.
   

Based on drug class, the stomach cancer treatment market is divided into PD-1/PD-L1 inhibitors, HER2 antagonists, VEGFR2 antagonists, and other drug classes. The PD-1/PD-L1 inhibitors of the market is forecasted to reach USD 5.6 billion by 2032.
 

• PD-1 (programmed cell death protein 1) and PD-L1 (programmed death-ligand 1) are proteins that play a key role in regulating the immune system. Cancer cells can exploit these proteins to evade immune detection. PD-1/PD-L1 inhibitors work by blocking this interaction, allowing the immune system to recognize and attack cancer cells more effectively.
   
• These inhibitors have shown efficacy in patients with advanced or metastatic gastric cancer. They offer a new treatment option for patients who have progressed on standard therapies.
   
• Further, clinical trials have demonstrated that PD-1/PD-L1 inhibitors can improve overall survival and progression-free survival in patients with advanced gastric cancer compared to traditional chemotherapy alone. Thus, escalating the growth of the market.
   

Based on route of administration, the stomach cancer treatment market is segmented into oral and injectable. The injectable segment accounted for USD 3 billion in 2023.
 

• Injectable treatments provide systemic therapy, they can reach cancer cells throughout the body via the bloodstream. This is crucial in treating gastric cancer, which can spread (metastasize) to distant organs such as the liver, lungs, or peritoneum.
   
• Injectable chemotherapy agents, such as fluorouracil (5-FU), cisplatin, oxaliplatin, and paclitaxel, are commonly used in the treatment of gastric cancer. These drugs can be administered intravenously (IV) or subcutaneously (under the skin), allowing for precise dosing and delivery directly into the bloodstream.
   
• Moreover, injectable treatments are typically administered in a clinical setting by trained healthcare professionals, ensuring accurate dosing and monitoring of potential side effects. This allows for precise management of treatment schedules and adjustments based on individual patient responses. Thus, driving the growth of the market.
   

Based on distribution channel, the stomach cancer treatment market is bifurcated into hospital pharmacies, specialty & retail pharmacies, and other distribution channels. The hospital pharmacies segment is forecasted to reach USD 7.5 billion by 2032.
 

• Hospital pharmacies stock and dispense specialized medications used in the treatment of stomach cancer, including chemotherapy drugs, targeted therapies, immunotherapy agents (such as PD-1/PD-L1 inhibitors), and supportive care medications. They ensure timely availability of these medications, which is crucial for initiating and maintaining treatment protocols.
   
• Some medications for stomach cancer treatment may require compounding to tailor dosages or formulations to individual patient needs. Hospital pharmacies have the expertise and facilities to safely prepare compounded medications, ensuring precise administration and adherence to treatment plans.
   
• Further, they adhere to stringent quality control measures to ensure the safety and efficacy of medications used in stomach cancer treatment. They verify medication orders, monitor for potential drug interactions, and conduct thorough checks to prevent medication errors.
   

The growth of the stomach cancer treatment market in the U.S. is projected to reach USD 5.3 billion by 2032.
 

• The rising prevalence of stomach cancer in the U.S. is a significant market driver. For instance, according to the American Cancer Society, in 2024, incidence of stomach cancer in the U.S. accounted for approximately 26,890 new cases (16,160 in men and 10,730 in women) and about 10,880 deaths 6,490 men and 4,390 women.
   
• The U.S. Food and Drug Administration (FDA) has stringent but efficient processes for approving new cancer treatments, ensuring that therapies are both safe and effective. The FDA's expedited review programs, like Breakthrough Therapy Designation, accelerate the availability of promising new treatments.
   

The stomach cancer treatment market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The UK is home to world-renowned research institutions such as Cancer Research UK, the Institute of Cancer Research (ICR), and the Francis Crick Institute. These institutions conduct cutting-edge research in oncology, including stomach cancer.
   
• The UK participates in numerous clinical trials for new cancer treatments, providing patients with an access to innovative therapies and contributing to global knowledge on stomach cancer.
   

Japan stomach cancer treatment market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Japanese researchers and pharmaceutical companies are at the forefront of developing novel therapies, including targeted therapies and immunotherapies tailored to the genetic and molecular profiles of stomach cancer patients.
   
• The Pharmaceuticals and Medical Devices Agency (PMDA) in Japan ensures that new treatments are safe and effective. The PMDA has pathways for accelerated approval of innovative therapies, facilitating quicker access to new treatments for patients.
   

The stomach cancer treatment market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• Saudi Arabia has established state-of-the-art medical facilities, such as King Faisal Specialist Hospital and Research Centre (KFSHRC), which provide comprehensive cancer care and attract top medical professionals from around the world.
   
• Saudi Arabia collaborates with leading international research institutions and universities to advance cancer research. These collaborations bring cutting-edge knowledge and innovations to the country.
   

Stomach Cancer Treatment Market Share

The stomach cancer therapeutics sector is highly competitive, featuring a mix of major global companies and smaller to medium-sized companies striving for market share. A crucial element of market strategy is the continuous introduction of innovative products utilizing diverse technologies. Leading industry players hold significant influence in this dynamic landscape, often driving advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are vital for strengthening market positions and expanding global footprints amid evolving regulatory landscapes.
 

Stomach Cancer Treatment Market Companies

Some of the eminent market participants operating in the stomach cancer treatment industry include:

• AstraZeneca PLC
• Bristol Myers Squibb Company
• Bayer AG
• Biocon Limited
• Celltrion Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Ipsen Pharma
• Merck & Co., Inc.
• Novartis AG
• Otsuka Holdings Co., Ltd.
• Pfizer Inc.
• Samsung Biologics Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Viatris Inc.
   

Stomach Cancer Treatment Industry News:

• In April 2024, Novartis announced FDA approval of Lutathera for treating pediatric patients aged 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut NETs. This approval marks a significant milestone in pediatric oncology, addressing previously unmet medical needs and providing new treatment options that aim to improve outcomes for young patients facing these rare and challenging cancers.
   
• In April 2021, Bristol-Myers Squibb Company received Food and Drug Administration approval for nivolumab (Opdivo) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma. This approval benefited the company by enhancing its oncology portfolio, increasing market share, and providing a competitive edge in the immunotherapy market.
   

The stomach cancer treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Chemotherapy
• Immunotherapy
• Targeted therapy

Market, By Indication

• Gastric cancer/ gastroesophageal junction cancer
• Gastrointestinal stromal tumors

Market, By Drug Class

• PD-1/PD-L1 inhibitors
• HER2 antagonists
• VEGFR2 antagonists
• Other drug classes

Market, By Route of Administration

• Oral
• Injectable

Market, By Distribution Channel

• Hospital pharmacies
• Specialty & retail pharmacies
• Other distribution channels

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa